Mountain Pacific Investment Advisers Inc. ID Has $33.78 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Mountain Pacific Investment Advisers Inc. ID grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 142,904 shares of the medical research company’s stock after acquiring an additional 9,723 shares during the period. Charles River Laboratories International accounts for approximately 2.1% of Mountain Pacific Investment Advisers Inc. ID’s holdings, making the stock its 19th largest position. Mountain Pacific Investment Advisers Inc. ID’s holdings in Charles River Laboratories International were worth $33,783,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Czech National Bank boosted its stake in Charles River Laboratories International by 47.9% during the 3rd quarter. Czech National Bank now owns 8,961 shares of the medical research company’s stock valued at $1,756,000 after purchasing an additional 2,902 shares during the period. Asset Management One Co. Ltd. lifted its position in shares of Charles River Laboratories International by 7.7% in the 3rd quarter. Asset Management One Co. Ltd. now owns 20,573 shares of the medical research company’s stock worth $4,032,000 after acquiring an additional 1,474 shares during the period. North Growth Management Ltd. lifted its position in Charles River Laboratories International by 15.6% in the third quarter. North Growth Management Ltd. now owns 37,000 shares of the medical research company’s stock worth $7,261,000 after purchasing an additional 5,000 shares during the period. Handelsbanken Fonder AB lifted its position in Charles River Laboratories International by 10.2% in the third quarter. Handelsbanken Fonder AB now owns 8,637 shares of the medical research company’s stock worth $1,693,000 after purchasing an additional 800 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC acquired a new stake in Charles River Laboratories International during the third quarter worth $209,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 0.5 %

NYSE CRL opened at $229.03 on Friday. The firm has a market cap of $11.80 billion, a P/E ratio of 24.87, a P/E/G ratio of 1.88 and a beta of 1.40. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The stock’s 50-day moving average is $253.48 and its 200-day moving average is $222.64.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. Charles River Laboratories International’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.98 earnings per share. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. UBS Group upped their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Citigroup lifted their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. upped their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Finally, Evercore ISI boosted their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $253.23.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).